CRDMO/CTDMO模式
Search documents
大摩:予药明康德(02359)“增持”评级 目标价升至143.5港元
智通财经网· 2026-02-20 09:18
Core Viewpoint - Morgan Stanley has issued a report maintaining an "Overweight" rating for WuXi AppTec (02359), citing an increase in gross margin and adjusting its earnings forecast for 2026 to 2030 upwards by 0% to 3% [1] Group 1: Earnings Forecast - The target price for WuXi AppTec has been raised from HKD 143 to HKD 143.5 [1] - The expected compound annual growth rate (CAGR) for earnings from 2024 to 2027 is projected to be 24% [1] Group 2: Competitive Advantage - The company is recognized for its unique CRDMO/CTDMO model and platform advantages [1] - WuXi AppTec has the highest number of early-stage projects among domestic competitors in China, providing stronger visibility for long-term growth compared to peers [1]